US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

13.10

+0.0000

Volume:88.77K

Turnover:1.16M

Market Cap:724.18M

PE:-8.09

High:13.11

Open:13.10

Low:13.09

Close:13.10

Loading ...

Overview Company News Filings

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

DuPont Launches Tyvek® with Renewable Attribution in Support of Sustainable Healthcare Packaging

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

BRIEF-RA Capital Management Reports 9.7% Passive Stake In Monopar Therapeutics

Regional SA de Cv (MEX:RA) Q3 2024 Earnings Call Highlights: Strong Loan Growth and Strategic ...

Dividend Investor Earning $10,200 a Month With $977,000 Shares His Portfolio: Top 7 Stocks

Press Release: Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

RA International Wins U.N. Contract Valued at Up to $70 Million

Brookfield Real Assets Income Fund Inc. Announces Quarterly Webcast

CPF Special Accounts for those 55 and above to be closed starting Jan after Bill passes

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc

Press Release: Brookfield Real Assets Income Fund Inc. Declares Q4 2024 Distribution Schedule

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":13.1,"timestamp":1742409151052,"preClose":13.1,"halted":0,"volume":88774,"delay":0,"changeRate":0,"change":0,"floatShares":55280700,"shares":55280700,"eps":-1.61933,"lyrEps":0,"amount":1163230.489946,"amplitude":0.001527,"volumeRatio":0.495971,"dividePrice":1.416,"prevYearClose":13.32,"fiveDayClose":13.26,"twentyDayClose":13.44},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55280700,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.495971,"shares":55280700,"dividePrice":1.416,"high":13.11,"amplitude":0.001527,"preClose":13.1,"low":13.09,"week52Low":12.165,"pbRate":"--","week52High":13.77,"institutionHeld":0,"latestPrice":13.1,"committee":-0.655405,"eps":-1.61933,"divideRate":0.108092,"volume":88774,"delay":0,"ttmEps":-1.61933,"open":13.1,"prevYearClose":13.32,"prevWeekClose":13.11,"prevMonthClose":13.35,"prevQuarterClose":13.32,"fiveDayClose":13.26,"twentyDayClose":13.44,"sixtyDayClose":13.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2025-03-13","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-13","defaultRemindTime":1741872600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-27","payableDate":"2025-03-13","currency":"USD","dateTimestamp":1741838400000,"payDate":"2025-03-27"},{"date":"2025-02-06","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-06","defaultRemindTime":1738852200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-20","payableDate":"2025-02-06","currency":"USD","dateTimestamp":1738818000000,"payDate":"2025-02-20"},{"date":"2025-01-10","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-09","defaultRemindTime":1736519400000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-23","payableDate":"2025-01-09","currency":"USD","dateTimestamp":1736485200000,"payDate":"2025-01-23"},{"date":"2025-01-09","symbol":"RA","amount":0.118,"announcedDate":"2024-12-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-09","defaultRemindTime":1736433000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-23","payableDate":"2025-01-09","currency":"USD","dateTimestamp":1736398800000,"payDate":"2025-01-23"},{"date":"2024-12-10","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-10","defaultRemindTime":1733841000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-10","currency":"USD","dateTimestamp":1733806800000,"payDate":"2024-12-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2482700781","title":"Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2482700781","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482700781?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:55","pubTimestamp":1731416100,"startTime":"0","endTime":"0","summary":"Reported positive YTD 2024 Adjusted EBITDA of $1.4 million. Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million. ZYNRELEF  extended-release solution Vial Access Needle  approved in September and on track for Q4 2024 launch. CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment in both the hospital outpatient department and ambulatory surgical center settings of care. \"We are pleased to report that with our prudent financial management and continued revenue growth we were able to achieve positive Adjusted EBITDA for the quarter,\" said Craig Collard, Chief Executive Officer. \"The future looks bright as we continue to grow all product revenue. The CrossLink partnership roll out, FDA approval of the VAN in September, and inclusion in the CMS Final Rule Non-Opioid Policy for Pain Relief, positions ZYNRELEF for significant growth within the surgical setting.\"","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FfkbfGCDs.TkHMBL0VTHOQ--~B/aD0xNDk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/84ed97d8520041f08c01be19219d37fc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FfkbfGCDs.TkHMBL0VTHOQ--~B/aD0xNDk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/84ed97d8520041f08c01be19219d37fc"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/heron-therapeutics-announces-third-quarter-125500353.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heron-therapeutics-announces-third-quarter-125500353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CINV","HRTX","BK4135","MEC","BK4161","AC","BK4139","BK4563","RA","B"],"gpt_icon":0},{"id":"2481884791","title":"DuPont Launches Tyvek® with Renewable Attribution in Support of Sustainable Healthcare Packaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2481884791","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481884791?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:00","pubTimestamp":1730988000,"startTime":"0","endTime":"0","summary":"WILMINGTON, Del., Nov. 7, 2024 /PRNewswire/ -- DuPont  today announced the launch of Tyvek with Renewable Attribution , an extension of the existing portfolio of Tyvek products for healthcare packaging that offers a significantly reduced carbon footprint, helping to enable more sustainable healthcare packaging. The carbon footprint reduction for Tyvek with Renewable Attribution is enabled by the partial replacement of fossil fuel feedstock with certified bio-circular feedstock during the production of raw materials used in Tyvek manufacturing. This is achieved through the mass balance approach, in accordance with International Sustainability and Carbon Certification .","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oxISBb_n9xgVEOMtlcWGoQ--~B/aD0xMTY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2afc4d09101aeb9068e83f4cbae39368","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oxISBb_n9xgVEOMtlcWGoQ--~B/aD0xMTY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2afc4d09101aeb9068e83f4cbae39368"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/dupont-launches-tyvek-renewable-attribution-140000263.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dupont-launches-tyvek-renewable-attribution-140000263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","LU0052756011.USD","BK4109","LU0128525689.USD","LU0211328371.USD","LU0310799852.SGD","LU2236285917.USD","BK4588","LU1267930490.SGD","LU0310800965.SGD","LU0211327993.USD","RA","DD","BK4504","BK4137","LU1267930227.SGD","BK4585"],"gpt_icon":0},{"id":"2481128904","title":"Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481128904","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481128904?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"New data for investigational nipocalimab in Sjgren's Disease  and new research on the impact of TREMFYA  in psoriatic arthritis  will be highlighted across three oral sessions and a plenary session. Results from the Phase 2 DAHLIAS study of nipocalimab in SjD show nipocalimab met the primary endpoint with a reduction in ClinESSDAI score from baseline and other key efficacy endpoints at Week 24 compared with placebo, presented in a plenary session. Results from the PsABIOnd observational study highlight the patient-reported impact in psoriatic arthritis  disease burden following treatment with TREMFYA, presented as an oral presentation. SPRING HOUSE, Pa., Nov. 7, 2024 /PRNewswire/ -- Johnson & Johnson  announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology  2024 Annual Meeting. Presentations include three oral sessions and a plenary session, highlighting new data for investigational nipo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZX6jJmV7ZALxLT9mcKxo.w--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZX6jJmV7ZALxLT9mcKxo.w--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/johnson-johnson-advances-leadership-rheumatic-130000353.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnson-advances-leadership-rheumatic-130000353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["D","IE000M9KFDE8.USD","ET","IE00BZ18W340.USD","BK4568","BK4218","PK","BK4094","BK4592","PD","IE00B1BXHZ80.USD","IE00BD4GTW91.USD","IE00BMG7P587.USD","RF","LU1032466523.USD","LU0122379950.USD","LU0882574055.USD","IE0002270589.USD","BK4144","BK4007","IE0009355771.USD","RA","IE00BD4GTT62.SGD","FL","LU1066053197.SGD","SLE","IE00B42XCP33.USD","LU0114720955.EUR","LU0795875086.SGD","LU1074936037.SGD","ACR","IE00B3T34201.USD","LU1066051811.HKD","LU1196500208.SGD","IE00BMG7P702.HKD","LU0203347892.USD","LU0098860793.USD","IE00BMG7P694.USD","LU0345769128.USD","BK4590","IE00BD4GTV84.USD","IE00BFTCPJ56.SGD","JNJ","IE00BDGV0183.EUR","IIM","BK4566","BK4532","IE00BVYPNW00.USD","BK4550","LU1057294990.SGD"],"gpt_icon":0},{"id":"2481990804","title":"Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481990804","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481990804?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:01","pubTimestamp":1730980860,"startTime":"0","endTime":"0","summary":"Global Phase 1 study of CLN-978 in systemic lupus erythematosus  cleared to initiate in U.S. and Australia; initial clinical data expected in Q4 2025. CLN-619 on-track for initial expansion cohort data in endometrial and cervical cancers in Q2 2025. \"We are making meaningful progress in executing our strategic plans for CLN-978 in autoimmune diseases while simultaneously advancing our oncology pipeline,\" said Nadim Ahmed, Chief Executive Officer of Cullinan Therapeutics. \"We have secured clearance from the U.S. Food and Drug Administration  for our IND application and Human Research Ethics Committee  approval in Australia to initiate our global Phase 1 study for CLN-978 in moderate to severe SLE. These important regulatory clearances position us to share initial clinical data for CLN-978 in the fourth quarter of 2025. We also continue to make significant progress in advancing our oncology portfolio, with data from two of our key programs expected in 2025. For CLN-619, we remain on trac","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","SITC","BK4139","ACR","BK4077","SLE","CGEM","BK4080","BK4110","BK4231"],"gpt_icon":0},{"id":"2481970542","title":"Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481970542","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481970542?lang=en_us&edition=fundamental","pubTime":"2024-11-07 19:30","pubTimestamp":1730979000,"startTime":"0","endTime":"0","summary":"Five Investigational New Drug  applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402. Proof of concept data from batoclimab trial in Graves’ disease  demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs ; initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year end. IND cleared for IMVT-1402 in rheumatoid arthritis , with potential best-in-class profile in difficult-to-treat  RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025. On track to initiate potentially registrational trials with IMVT-1402 in four to five indications, inclusive of GD and D2T RA, by March 31, 2025. Immunovant to host development update call today, November 7, at 8 a.m. ET. “We are also excited to announce expansion of our IMVT-1402 development program into Rheumatology","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6EDLPKqoXNjuSfR3I70YPQ--~B/aD0zMjt3PTIwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/fca93fc54aa06d47cf61540482b0a710","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6EDLPKqoXNjuSfR3I70YPQ--~B/aD0zMjt3PTIwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/fca93fc54aa06d47cf61540482b0a710"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovant-provides-development-updates-reports-113000731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","BK4550","BK4585","MG","RA","IE00B66KJ199.SGD","BK4187","BK4588","IE00B19Z4B17.USD","BK4123","GD","IE00B7SZL793.SGD","IE0031619046.USD","BK4566","LU0170899867.USD","BK4139","IMVT"],"gpt_icon":0},{"id":"2481651597","title":"Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481651597","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481651597?lang=en_us&edition=fundamental","pubTime":"2024-11-06 05:15","pubTimestamp":1730841300,"startTime":"0","endTime":"0","summary":"Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis  in December 2024. Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis  in February 2025. Phase 1 trial initiated in healthy volunteers for ANB033, our anti-CD122 antagonist. \"We remain confident in the potential best-in-class profiles of our programs targeting BTLA and PD-1 co-inhibitory receptors to drive differentiated results as we approach multiple clinical catalysts and value drivers for Anaptys, including top-line Phase 2b data in AD for ANB032, our BTLA agonist, in December. We’ve also completed enrollment for the Phase 2b trial of rosnilimab, our PD-1 agonist, in RA and are narrowing our guidance for top-line data to February 2025,\" said Daniel Faga, president and chief executive officer of Anaptys. \"Additionally, enrollment in healthy volunteers has commenced for the Phase 1 trial for ANB033, our anti-CD122 antagonist, and we look forward to disclosin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hNSpY3WrOwZBYZIubo3WCQ--~B/aD03MTt3PTMwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/db05bbcd54c049ea022832fa373c4161","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hNSpY3WrOwZBYZIubo3WCQ--~B/aD03MTt3PTMwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/db05bbcd54c049ea022832fa373c4161"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anaptys-announces-third-quarter-2024-211500418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["L","BK4585","BK4144","BK4107","GPP","BK4139","LU0053666078.USD","RA","TEP","ANAB","BK4588","BK4590"],"gpt_icon":0},{"id":"2480093161","title":"BRIEF-RA Capital Management Reports 9.7% Passive Stake In Monopar Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2480093161","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480093161?lang=en_us&edition=fundamental","pubTime":"2024-11-01 06:00","pubTimestamp":1730412022,"startTime":"0","endTime":"0","summary":"Oct 31 (Reuters) - Monopar Therapeutics Inc   :   * RA CAPITAL MANAGEMENT LP REPORTS 9.7% PASSIVE STAKE IN MONOPAR THERAPEUTICS INC AS OF OCT 24 - SEC FILINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RA","MNPR"],"gpt_icon":0},{"id":"2479270024","title":"Regional SA de Cv (MEX:RA) Q3 2024 Earnings Call Highlights: Strong Loan Growth and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2479270024","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479270024?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:00","pubTimestamp":1730286033,"startTime":"0","endTime":"0","summary":"Net Income: MXN1,604 million, a 3% increase year-on-year.Return on Average Equity: Expanded by 83 basis points year-on-year to 21.7%.Loan Growth: 30% year-on-year, outperforming the banking sector's 12% growth.Core Deposits: Increased 11% year-on-year compared to the sector's 9% expansion.Financial Margin: Expanded by 12% year-on-year and 4% quarter-on-quarter.Card and Merchant Fees: Increased by 15% year-on-year.Efficiency Ratio: 39.5%, a year-on-year contraction of 223 basis points.Branch Expansion: 22 new locations in the last 12 months, with plans for 20 additional branches in 2025.Nonperforming Loans Ratio: Improved by 11 basis points year-on-year to 1.2%.Cost of Risk: Consolidated cost of risk at 1%, above the guidance range of 0.7% to 0.9%.Hey Banco Efficiency Ratio: Increased to 69.3%, a 12% year-on-year improvement.Hey Pago Monthly Billing: Expanded by 21% year-on-year, reaching MXN12,027 million.Regional SA de Cv  reported a strong 30% year-on-year loan growth, significantly ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regional-sa-cv-mex-ra-110033443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RGNLF","RA"],"gpt_icon":0},{"id":"2478645821","title":"Dividend Investor Earning $10,200 a Month With $977,000 Shares His Portfolio: Top 7 Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2478645821","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478645821?lang=en_us&edition=fundamental","pubTime":"2024-10-27 23:00","pubTimestamp":1730041219,"startTime":"0","endTime":"0","summary":"Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.There is more than one way to achieve financial success through investing. Some prefer riding the gains of tech growth stocks to build wealth, while others enjoy collecting dividend income alongside portfolio growth. Let's see an interesting success story of an investor crushing it with the latter strategy.In June last year, a dividend investor shared his detailed income report with portfolio screenshots on r/Dividends, a discussion board for income investors with more than 600,000 members. The investor said he earned about $10,200 per month in dividends or $122,930 per year. He said his total portfolio value was $977,000, excluding reinvested dividends, with a yield of 12.5%.Your biggest returns may not come from the stock market. Invest the way colleges, pension funds, and the 1% do.Benzinga Readers: Earn a 1% return boost on your first EquityMultiple investment when you sign up here *","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AEB8.SB36eCTXPDG41jC_w--~B/aD00ODA7dz03MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/benzinga_79/92101a118e7ca3ce8730ca39815301c3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AEB8.SB36eCTXPDG41jC_w--~B/aD00ODA7dz03MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/benzinga_79/92101a118e7ca3ce8730ca39815301c3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dividend-investor-earning-10-200-150019642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3PB1722.GBP","LU0289960550.SGD","LU0154245756.USD","LU2592432038.USD","IE00B3QW5Z07.USD","LU1989771016.USD","GOF","IE00BGHQF631.EUR","LU1074936037.SGD","RA","LU1670628061.USD","TT","IE00B29SXK94.USD","LU1069347547.HKD","US12M.BOND","LU1718418525.SGD","US7Y.BOND","LU1162221912.USD","US30Y.BOND","US10Y.BOND","US3Y.BOND","LU1481011911.USD","LU1599440770.SGD","LU2430703251.USD","US5Y.BOND","LU2211817866.USD","QYLD","IE0004091025.USD","IE00B29SXL02.USD","LU1670627923.USD","US2Y.BOND","SG9999011175.SGD","LU2552382058.USD","SO","FDN","BIT","LU2552382132.HKD","IE00BMG7P819.SGD","BK4533","US912797HE00.BOND","PGR","IE00BKVL7J92.USD","IE0005OL40V9.USD","IE00BN29S564.USD","LU0154245673.USD","US6M.BOND","BLK","HYT","LU0323240290.USD"],"gpt_icon":1},{"id":"2477689957","title":"Press Release: Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2477689957","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477689957?lang=en_us&edition=fundamental","pubTime":"2024-10-24 19:30","pubTimestamp":1729769400,"startTime":"0","endTime":"0","summary":"NEW YORK and MELBOURNE, Australia, Oct. 24, 2024  -- Incannex Healthcare Inc. , , a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer  effective immediately. Dr. Barbato's drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals, AbbVie, Biogen, Novartis, and Solvay. He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.\"We are delighted to welcome Dr. Barbato to Incannex as our Chief Medical Officer. With an established track record in directing drug development through late-stage clinical trials and multiple product launches, Lou is a valuable addition to the Incannex team,\" said Joel Latham, Incannex's President and Chief Executive Officer. \"Lou's","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4510","BK4563","BK4085","BK4022","IXHL","BK4007","R","GSK.UK","BK4232","RA","LU1829250122.USD","GSK","BK4532","BK4585","BK4167","BK4588","AHI","CMO","BK4097","IH"],"gpt_icon":1},{"id":"2477782955","title":"RA International Wins U.N. Contract Valued at Up to $70 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2477782955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477782955?lang=en_us&edition=fundamental","pubTime":"2024-10-24 14:57","pubTimestamp":1729753020,"startTime":"0","endTime":"0","summary":"RA International won a new three-year contract with the United Nations Interim Security Force for Abyei, between Sudan and South Sudan.The London-listed construction and facility-support services company said Thursday that the contract is valued between $60 million and $70 million for three years, with the option of being extended a further two.Under the new contract, the group will provide camp management services, it said.RA International has been supporting UNISFA in Abyei since 2020 through a different contract worth $5 million for the provision of manpower.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2477456796","title":"Brookfield Real Assets Income Fund Inc. Announces Quarterly Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2477456796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477456796?lang=en_us&edition=fundamental","pubTime":"2024-10-24 04:45","pubTimestamp":1729716300,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct. 23, 2024  -- Brookfield Public Securities Group LLC  will host a webcast for Brookfield Real Assets Income Fund Inc.   on Wednesday, October 30, 2024 at 4:30pm ET. PSG will provide an update on the Fund and on general market conditions.Audio only: +1 323-794-2442 or 800-289-0462Event Code: 612518. It is not necessary to dial into the audio conference, unless you are unable to join via the webcast URL.A fund’s investment objectives, risks, charges and expenses must be considered carefully before investing. The prospectus contains this and other important information about the investment company. Read the prospectus carefully before investing.Quasar Distributors, LLC, provides filing administration for Brookfield Real Assets Income Fund Inc.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YTSsXiz4gpU6BLRbOjEZTw--~B/aD01MTt3PTMwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/9050204b5988381449928f05e41fc8f8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YTSsXiz4gpU6BLRbOjEZTw--~B/aD01MTt3PTMwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/9050204b5988381449928f05e41fc8f8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brookfield-real-assets-income-fund-204500845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RA"],"gpt_icon":0},{"id":"2475432363","title":"CPF Special Accounts for those 55 and above to be closed starting Jan after Bill passes","url":"https://stock-news.laohu8.com/highlight/detail?id=2475432363","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475432363?lang=en_us&edition=fundamental","pubTime":"2024-10-14 19:50","pubTimestamp":1728906600,"startTime":"0","endTime":"0","summary":"More than 99 per cent of CPF members aged 55 and above would be able to transfer all their Special Account savings to their Retirement Account, if they wish to do so.","market":"sg","thumbnail":"https://onecms-res.cloudinary.com/image/upload/s--5kNePTmc--/c_crop,h_1406,w_2500,x_0,y_0/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:mediacorp,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2021/12/18/20161117_mf_cpf_bishan.jpg?itok=4Im35Dvi","type":0,"news_type":0,"thumbnails":["https://onecms-res.cloudinary.com/image/upload/s--5kNePTmc--/c_crop,h_1406,w_2500,x_0,y_0/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:mediacorp,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2021/12/18/20161117_mf_cpf_bishan.jpg?itok=4Im35Dvi"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/cpf-special-account-parliament-over-55-retirement-4677261","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["RA","BK4211","CPF","BK4017","HPS"],"gpt_icon":0},{"id":"2474774963","title":"Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids","url":"https://stock-news.laohu8.com/highlight/detail?id=2474774963","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474774963?lang=en_us&edition=fundamental","pubTime":"2024-10-11 04:00","pubTimestamp":1728590400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc.  , a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI  injectable emulsion and SUSTOL  extended-release injection for Chemotherapy Induced Nausea and Vomiting  prevention and APONVIE for Postoperative Nausea and Vomiting  prevention given the temporary shortage of intravenous  fluids which is expected as the result of Hurricane Helene. As alternatives to products that require dilution with IV fluids, CINVANTI, SUSTOL, and APONVIE are supplied in ready-to-administer formulations that do not requireadditional dilution with IV fluids in what may be a time of critical shortage.\"In the wake of Hurricane Helene, and with the recently announced potential supply disruption for IV fluids, Heron has received outreach from several health systems preparing to maintain continuity of care,\" saidCraig Collard, Chief Executive Officer of Heron. \"Our team is committed to ensuring timely de","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FfkbfGCDs.TkHMBL0VTHOQ--~B/aD0xNDk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/84ed97d8520041f08c01be19219d37fc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FfkbfGCDs.TkHMBL0VTHOQ--~B/aD0xNDk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/84ed97d8520041f08c01be19219d37fc"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/heron-therapeutics-reaffirms-availability-ample-200000749.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heron-therapeutics-reaffirms-availability-ample-200000749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4563","MEC","AC","CINV","BK4139","HRTX","RA","BK4161"],"gpt_icon":0},{"id":"2473452908","title":"RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2473452908","media":"GuruFocus.com","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473452908?lang=en_us&edition=fundamental","pubTime":"2024-10-08 09:10","pubTimestamp":1728349827,"startTime":"0","endTime":"0","summary":"On September 27, 2024, RA Capital Management, L.P., a prominent investment firm, made a significant move in the biopharmaceutical sector by acquiring 2,210,589 shares of Bioage Labs Inc . This transaction, valued at $21 per share, marks a new holding for the firm, reflecting a strategic investment in the healthcare industry. The acquisition not only diversifies RA Capital's portfolio but also underscores its commitment to investing in innovative companies tackling major healthcare challenges.Based in Boston, RA Capital Management, L.P. is renowned for its focus on healthcare and financial services sectors. With a robust portfolio that includes top holdings like Ascendis Pharma AS  and Rhythm Pharmaceuticals Inc , the firm manages an equity portfolio worth approximately $7.56 billion. RA Capital's investment philosophy emphasizes substantial engagement in sectors that promise significant technological or therapeutic advancements.The acquisition of a 0.61% position in Bioage Labs by RA C","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JTt5bo0JSKtQ3XtJrY3fJQ--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/9802aef1fe4cb0ac29db2bff39d71eb6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JTt5bo0JSKtQ3XtJrY3fJQ--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/9802aef1fe4cb0ac29db2bff39d71eb6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ra-capital-management-l-p-011027241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","MNQmain","BK4588","RA","BIOA","LU0109394709.USD","LU0889565916.HKD","PSQ","NQmain",".IXIC","QLD","SQQQ","RYTM","BK4585","LU0320765992.SGD","BK4139","ASND","QID"],"gpt_icon":1},{"id":"2472591183","title":"Press Release: Brookfield Real Assets Income Fund Inc. Declares Q4 2024 Distribution Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2472591183","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472591183?lang=en_us&edition=fundamental","pubTime":"2024-10-01 04:19","pubTimestamp":1727727540,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 30, 2024  -- Brookfield Real Assets Income Fund Inc.   today announced that its Board of Directors  declared the Fund's monthly distributions for October, November and December 2024.Investing involves risk; principal loss is possible. Past performance is not a guarantee of future results.Foreside Fund Services, LLC is the distributor for the Fund.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":3,"totalSize":58}]}}